VEGFA and non-small cell lung carcinoma: When combined with chemotherapy, bevacizumab (an anti-VEGF monoclonal antibody) has been shown to prolong the survival of patients with cancer, especially for those with metastatic colorectal cancer (mCRC) and non-small cell lung cancer (NSCLC).